Gerresheimer Navigates a Crisis of Confidence Amid Regulatory Scrutiny

German packaging firm Gerresheimer delays 2025 results after audit finds grave accounting deficiencies. Revenue and EBITDA guidance slashed amid regulatory pressure and a plunging share price.

The German packaging specialist Gerresheimer finds itself in a precarious position, caught between regulatory pressure and a potential shareholder vote of confidence. The market's focus is squarely on whether the company can deliver its financial statements in a timely and transparent manner to restore stability.

Regulatory Pressure Intensifies with Expanded Audit

A significant overhang for the company is the escalating scrutiny from Germany's Federal Financial Supervisory Authority, BaFin. The regulator has broadened its examination beyond the 2024 consolidated financial statements to include a review of the 2025 half-year financial report. This move places multiple reporting periods under the microscope simultaneously.

The findings are serious. According to the company, an expanded audit conducted by a second auditing firm uncovered "grave deficiencies," primarily concerning revenue recognition and the valuation of inventories for both 2024 and 2025. Gerresheimer attributes these issues to violations of internal guidelines and IFRS accounting standards by individual employees.

This follows earlier corrections required for 2024, where €35 million in revenue and €24 million in adjusted EBITDA linked to bill-and-hold transactions were identified as erroneously booked. The 2025 half-year report also highlights balance sheet risk assessments related to the acquisition of Bormioli Pharma.

Financial Guidance Lowered and Reporting Delayed

Compounding the accounting problems, Gerresheimer has postponed the publication of its 2025 annual and consolidated financial statements. Initially scheduled for February 26, the release is now targeted for completion by March 31, 2026.

Operationally, management has tempered expectations. For the full year 2025, the company anticipates a revenue decline at the upper end of the -4% to -2% range (or slightly better). The forecast for the adjusted EBITDA margin has been reduced to 16.5% to 17.5%, down from the previous guidance of 18.5% to 19.0%. Adjusted earnings per share are projected to fall by a high double-digit percentage, with a negative result not ruled out. Additionally, Gerresheimer expects non-cash impairment charges of €220 to €240 million.

Share Price Reflects Deep Market Skepticism

The market's reaction has been severe. The recent closing price of €16.25 hovers just above the 52-week low of €15.57. The stock has plummeted -79.71% over the past twelve months and is down -41.38% since the start of the year. Technical indicators underscore the bearish sentiment: a 14-day RSI of 17.7 signals deeply oversold conditions, and the share price trades far below its 200-day moving average of €33.84.

Strategic Shifts: New Investor and Asset Sales

Amid this turmoil, a notable development is the entry of a specialized investor. On March 3, the CastleKnight Master Fund LP reported a voting rights stake of 4.08%, with the threshold crossing dated February 11, 2026. This suggests some capital sees potential in a turnaround narrative, despite the prevailing uncertainties.

Management is undergoing its own transition. Following the departures of CEO Dietmar Siemssen (end of October) and CFO Bernd Metzner, Wolf Lehmann has assumed the CFO role. Uwe Röhrhoff has been serving as interim CEO since November.

Looking ahead to 2026, Gerresheimer projects—before any M&A activity—revenue of €2.3 to €2.4 billion and an adjusted EBITDA margin of 18% to 19%, alongside a moderately positive free cash flow despite a weaker first half. To reduce debt, the company has mandated Morgan Stanley to sell its US subsidiary Centor and its international Moulded Glass business.

The Critical Path Forward

The calendar for regaining trust is now clearly defined. Key milestones include the publication of the annual report by March 31, 2026, a Q1 trading update on April 16, 2026, and the Annual General Meeting on June 3, 2026.

The March 31 deadline stands as the critical litmus test. A clean, comprehensible presentation of the financials could provide a first chance for confidence to stabilize. Without this crucial step, the near-term outlook for Gerresheimer shares is likely to remain under significant pressure.